Harvard researcher John Halpern has formed a company he hopes will bring to market a drug based on his research into the effects of lysergic acid diethylamide on cluster headaches, a rare but devastating condition that is as bad as it sounds. Halpern, a noted expert in the long-term effects of drug use, said research suggests chemicals present in LSD are an astonishingly effective cure for cluster headaches. Entheogen’s drug does not cause triptastic visions, Halpern said -- it is based on BOL-148, a non-hallucinogenic LSD derivative developed in the 1950s and 60s for research into the effects of LSD on the brain, when such was last in vogue.